BlastomaBrain™ Glioblastoma Model
Glioblastoma
Pre-clinicalActive
Key Facts
About Neurix
Neurix is a private, Switzerland-based biotech company leveraging human iPSC technology to create advanced 3D in vitro models of the brain for preclinical research. Its core business is providing specialized research services and proprietary model systems, such as its BlastomaBrain™ glioblastoma model, to pharmaceutical and academic partners to improve the predictability of neuroscience drug discovery. The company is led by a team with strong scientific and business backgrounds and has been supported by European research funding. Neurix operates as a pre-revenue platform and services company, focusing on neurodegenerative diseases and neuro-oncology.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |